Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate

被引:69
作者
Reddy, Joseph A.
Westrick, Elaine
Santhapuram, Hari K. R.
Howard, Stephen J.
Miller, Michael L.
Vetzel, Marilynn
Vlahov, Iontcho
Chari, Ravi V. J.
Goldmacher, Victor S.
Leamon, Christopher P.
机构
[1] Endocyte Inc, W Lafayette, IN 47906 USA
[2] ImmunoGen Inc, Cambridge, MA USA
关键词
D O I
10.1158/0008-5472.CAN-06-3894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
EC131, a new folate receptor (FR)-targeted drug conjugate, was prepared by covalently attaching the vitamin folic acid (FA) to a potent microtubule-inhibiting agent, maytansinoid DM1, via an intramolecular disulfide bond. When tested on cells in culture, EC131 was found to retain high affinity for FR-positive cells and to provide FR-specific cytotoxicity with an IC50 in the low nanomolar range. The activity of EC131 was completely blocked in the presence of an excess of free FA, and no activity was detected against FR-negative cells. When evaluated against s.c. FR-positive M109 tumors in BALB/c mice, EC131 showed marked antitumor efficacy. Furthermore, this therapeutic effect occurred in the apparent absence of weight loss or noticeable organ tissue degeneration. In contrast, no significant antitumor activity was observed in EC131-treated animals that were codosed with an excess of FA, thus demonstrating the targeted specificity of the in vivo activity. EC131 also showed marked antitumor activity against FR-positive human KB tumors, but not against FR-negative A549 tumors, in nude mice with no evidence of systemic toxicity during or after the therapy. In contrast, therapy with the free maytansinoid drug (in the form of DM1-S-Me) proved not to be effective against the KB model when administered at its maximum tolerated dose (MTD). Taken together, these results indicate that EC131 is a highly potent agent capable of producing therapeutic benefit in murine tumor models at sub-MTD levels.
引用
收藏
页码:6376 / 6382
页数:7
相关论文
共 52 条
[1]  
ARNOULD R, 1990, ANTICANCER RES, V10, P145
[2]   INTERNALIZATION AND INTRACELLULAR-TRANSPORT OF FOLATE-BINDING PROTEIN IN RAT-KIDNEY PROXIMAL TUBULE [J].
BIRN, H ;
SELHUB, J ;
CHRISTENSEN, EI .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (02) :C302-C310
[3]   Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule [J].
Birn, H ;
Nielsen, S ;
Christensen, EI .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1997, 272 (01) :F70-F78
[4]   Recent developments in the maytansinoid antitumor agents [J].
Cassady, JM ;
Chan, KK ;
Floss, HG ;
Leistner, E .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (01) :1-26
[5]  
CHARI RVJ, 1995, CANCER RES, V55, P4079
[6]  
CHARI RVJ, 1992, CANCER RES, V52, P127
[7]   Anti body-targeted chemotherapy with immunoconjugates of calicheamicin [J].
Damle, NK ;
Frost, P .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) :386-390
[8]   Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing [J].
Erickson, HK ;
Park, PU ;
Widdison, WC ;
Kovtun, YV ;
Garrett, LM ;
Hoffman, K ;
Lutz, RJ ;
Goldmacher, VS ;
Blättler, WA .
CANCER RESEARCH, 2006, 66 (08) :4426-4433
[9]   Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia [J].
Giles, F ;
Estey, E ;
O'Brien, S .
CANCER, 2003, 98 (10) :2095-2104
[10]   Delivery of molecular and cellular medicine to solid tumors (Reprinted from Advanced Drug Delivery Reviews, vol 26, pg 71-90, 1997) [J].
Jain, RK .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :149-168